Benjamin L L Clayton
Overview
Explore the profile of Benjamin L L Clayton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
498
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ziar R, Tesar P, Clayton B
Neurotherapeutics
. 2025 Feb;
:e00540.
PMID: 39939240
Astrocytes and oligodendrocytes, once considered passive support cells, are now recognized as active participants in the pathogenesis of Alzheimer's disease. Emerging evidence highlights the critical role that these glial cells...
2.
Clayton B, Barbar L, Sapar M, Kalpana K, Rao C, Migliori B, et al.
Cell Stem Cell
. 2024 Aug;
31(11):1701-1713.e8.
PMID: 39191254
Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system (CNS), resulting in neurological disability that worsens over time. While progress has been made in defining...
3.
Cohn E, Clayton B, Madhavan M, Lee K, Yacoub S, Fedorov Y, et al.
Nat Neurosci
. 2024 Mar;
27(5):836-845.
PMID: 38528201
Exposure to environmental chemicals can impair neurodevelopment, and oligodendrocytes may be particularly vulnerable, as their development extends from gestation into adulthood. However, few environmental chemicals have been assessed for potential...
4.
Clayton B, Kristell J, Allan K, Cohn E, Karl M, Jerome A, et al.
Nat Neurosci
. 2024 Feb;
27(4):656-665.
PMID: 38378993
Disease, injury and aging induce pathological reactive astrocyte states that contribute to neurodegeneration. Modulating reactive astrocytes therefore represent an attractive therapeutic strategy. Here we describe the development of an astrocyte...
5.
De Rossi P, Buggia-Prevot V, Clayton B, Vasquez J, van Sanford C, Andrew R, et al.
Mol Neurodegener
. 2023 Oct;
18(1):72.
PMID: 37784204
No abstract available.
6.
Clayton B, Barbar L, Sapar M, Rusielewicz T, Kalpana K, Migliori B, et al.
bioRxiv
. 2023 Aug;
PMID: 37577713
Multiple sclerosis (MS) is considered an inflammatory and neurodegenerative disease of the central nervous system, typically resulting in significant neurological disability that worsens over time. While considerable progress has been...
7.
Cohn E, Clayton B, Madhavan M, Yacoub S, Federov Y, Paul-Friedman K, et al.
bioRxiv
. 2023 Feb;
PMID: 36798415
Exposure to environmental chemicals can impair neurodevelopment. Oligodendrocytes that wrap around axons to boost neurotransmission may be particularly vulnerable to chemical toxicity as they develop throughout fetal development and into...
8.
Clayton B, Tesar P
Curr Opin Cell Biol
. 2021 Jun;
73:35-40.
PMID: 34153742
Differentiation of oligodendrocyte progenitor cells (OPCs) into myelination-capable mature oligodendrocytes is essential for proper function of the central nervous system. OPCs are tissue-resident stem cells that populate all regions of...
9.
Allan K, Hu L, Scavuzzo M, Morton A, Gevorgyan A, Cohn E, et al.
Cell Stem Cell
. 2020 Oct;
28(2):257-272.e11.
PMID: 33091368
Mammalian cells respond to insufficient oxygen through transcriptional regulators called hypoxia-inducible factors (HIFs). Although transiently protective, prolonged HIF activity drives distinct pathological responses in different tissues. Using a model of...
10.
Baldassari L, Feng J, Clayton B, Oh S, Sakaie K, Tesar P, et al.
Expert Rev Neurother
. 2019 Jun;
19(10):997-1013.
PMID: 31215271
: Approved disease-modifying therapies for multiple sclerosis (MS) lessen inflammatory disease activity that causes relapses and MRI lesions. However, chronic inflammation and demyelination lead to axonal degeneration and neuronal loss,...